Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $18.94 Analyst target: $35.50 Upside: 87.43%
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.